Philippe Beuzeboc

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 28, 2023

Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Published: May 04, 2021

French ccAFU guidelines - update 2020-2022: prostate cancer

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Published: December 22, 2020

French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Published: March 24, 2020

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 01, 2019

French ccAFU guidelines - Update 2018-2020: Prostate cancer

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Published: August 10, 2018

RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate French ccAFU guidelines – Update 2018–2020: Prostate cancer

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Published: August 10, 2018

French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.

Journal: Joint bone spine

Published: July 20, 2018

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Journal: European urology

Published: May 22, 2017

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].

Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].

French ccAFU guidelines - update 2020-2022: prostate cancer

French ccAFU guidelines - update 2020-2022: prostate cancer

French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020

French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

French ccAFU guidelines - Update 2018-2020: Prostate cancer

French ccAFU guidelines - Update 2018-2020: Prostate cancer

RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate French ccAFU guidelines – Update 2018–2020: Prostate cancer

RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate French ccAFU guidelines – Update 2018–2020: Prostate cancer

French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.

French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.

French CCAFU guidelines on prostate cancer: hormono-naive metastatic prostate cancer - update 2017

French CCAFU guidelines on prostate cancer: hormono-naive metastatic prostate cancer - update 2017

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.

Radium 223 dichloride for prostate cancer treatment.

Radium 223 dichloride for prostate cancer treatment.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.